Skip to main content

Table 3 Diabetes management in urban and remote Indigenous Australians and remote Indigenous Canadians

From: Cardiovascular disease risk profile and microvascular complications of diabetes: comparison of Indigenous cohorts with diabetes in Australia and Canada

 

Group 1: Remote Australian (n = 37)

Group 2: Urban

Australian (n = 94)

Group 3: Remote Canadian (n = 188)

Diet/nil glucose-lowering medications

11 (30%)

9 (10%)

78 (41%)

Metformin

24 (65%)

52 (57%)

83 (44%)†‡

Sulphonylurea

11 (30%)

32 (35%)

62 (33%)

Acarbose

0

2 (2%)

1 (0.5%)

Thiazolidinedione

0

6 (7%)

5 (3%)

Insulin

0

18 (19%)†

34 (18%)†

Aspirin*

16 (43%)

39 (43%)

36 (32%)

HMG CoA reductase inhibitor*

9 (24%)

35 (37%)

23 (20%)‡

ACE inhibitor or A2RA*

23 (62%)

59 (63%)

73 (64%)

  1. Data are n (%).
  2. † p < 0.0001 when compared to Group 1
  3. ‡ p < 0.05 compared to Group 2
  4. *n = 114 for Remote Canadian group
  5. HMG CoA, 3-hydroxy-3-methylglutaryl-CoA; ACE, angiotensin converting enzyme; A2RA, angiotensin-2 receptor antagonist.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840